KRAS and non-small cell lung carcinoma: TVB-2640, a selective and reversible inhibitor of fatty acid synthase (FASN) that exerts effects on KRAS mutant versus KRAS wild-type NSCLCs, is currently being tested in a phase 2 study that includes NSCLC patients harboring KRAS mutations since KRAS mutant cases are associated with lipogenic features (Clinicaltrials.gov Identifier: NCT03808558 (accessed on 24 February 2021)).